Commercializing Living Therapies with CCRM
Commercializing Living Therapies with CCRM
Latest Episodes
The CMC edge: Future-proofing cell and gene therapies for market
Featuring:Katy Spink, President and COO, Managing Partner, Dark Horse Consulting GroupCraig Beasley, Chief Technology Officer (CMC & Device), BlueRock Therapeutics***Chemistry, Manufacturing, and Controls (CMC) i...
Confronting misinformation in the cell and gene therapies field
Featuring:Megan Munsie, PhD, Group Leader, Stem Cell Ethics & Policy, Stem Cell Medicine, Murdoch Children's Research Institute; Prepare Theme Lead, Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW; Professor Emerging Tec...
Convergence, collaboration and commercialization in cell and gene therapies
Featuring:Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of TorontoAudrey Greenberg, MBA, CEO & Founder, AG Capital Advisor...
Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector
Reni Benjamin, Managing Director, Healthcare Equity Research at CitizensBrock Reeve, CEO and Co-founder, Eos BioInnovation***In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks wi...
Navigating commercialization: Regional hubs, global solutions
Featuring:Silvio Tiziani, CEO, CCRM AustraliaSarah Callens, CTO, CCRM Nordic***In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM...
